Plasma level of soluble tumor necrosis factor-related apoptosis-inducing ligand in patients with primary biliary cirrhosis: expression and clinical significance

Yan LIANG,Zai-xing YANG,Yan WANG,Chang LI,Wei-juan CAO,Ren-qian ZHONG
DOI: https://doi.org/10.3321/j.issn:0258-879X.2007.02.008
2007-01-01
Academic Journal of Second Military Medical University
Abstract:Objective: To determine the plasma level of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) in patients with primary biliary cirrhosis (PB0 and to explore its clinical significance. Methods: The plasma levels of sTRAIL were examined in 30 patients with PBC, 25 patients with chronic hepatitis and cirrhosis, and 30 healthy donors with ELISA. Meanwhile, the concentrations of plasma gamma7glutamyltransferase (GGT) and alkaline phosphatase (ALP) were examined and their correlation with sTRAIL was analyzed. Results: The plasma level of sTRAIL in PBC patients was (1 543.9 ± 344.2) pg/ml, which was significantly higher than that of healthy donors ([1 098.5±264.7] pg/ml, P<O.01); sTRAIL level in patients with chronic hepatitis and cirrhosis was (1 624.1±415.8) pg/ml, which was significantly higher than that of control ([1 098.5 ± 264.7] pg/ml, P<O.05). We also found that sTRAIL level was positively correlated with GGT and ALP concentrations in PBC patients (r=0.63,0.71,P<O.01), but not with those in patients with chronic hepatitis and cirrhosis (r=0.43,0.31,P>0.05). Conclusion: Plasma sTRAIL level is elevated in PBC patients and is correlated with GGT and ALP concentrations, indicating that sTRAIL may contribute to the impair of the intrahepatic bile ducts and is associated with the mobility of PBC.
What problem does this paper attempt to address?